Bartsch H, Malaveille C
International Agency for Research on Cancer, Lyon, France.
IARC Sci Publ. 1990(104):65-74.
To determine whether genotoxic and non-genotoxic carcinogens contribute similarly to the cancer burden in humans and which types of short-term test are more relevant for predicting human hazards, an analysis was performed on agents that were evaluated in IARC Monographs Supplements 6 and 7 for their carcinogenic effects in humans and animals and for activity in short-term genotoxicity tests. The prevalence of genotoxicity among four groups of agents, consisting of established human carcinogens (group 1, n = 30), probable human carcinogens (group 2A, n = 37), possible human carcinogens (group 2B, n = 113) and agents with limited evidence of carcinogenicity in animals (a subset of group 3, n = 66) was determined. Each of the groups 1, 2A and 2B contained a high proportion (80-90%) of genotoxic carcinogens, which were also multi-species or multi-tissue carcinogens. The distribution of carcinogenic potency in rodents did not reveal any specific characteristic of the human carcinogens in group 1 that would differentiate them from agents in groups 2A, 2B and many in group 3. Although limited by the data-base available through the Monographs series, this analysis implies that genotoxic carcinogens add more to the human cancer burden than non-genotoxic carcinogens. Thus, the continued use of in vitro/in vivo short-term tests, involving as endpoints DNA chromosomal or mutational damage, to identify genotoxic carcinogens or in the isolation of carcinogenic components in complex mixtures is fully justified. It is concluded that (a) an agent or complex mixture with unknown carcinogenic potential showing sufficient evidence of activity in genotoxicity assays in vitro or in vivo is likely to represent a hazard to humans and (b) an agent or complex mixture showing lack of activity in this spectrum of genotoxicity assays should undergo evaluation for carcinogenicity for rodent bioassay, in view of the present lack of validated short-term tests for non-genotoxic carcinogens.
为了确定遗传毒性致癌物和非遗传毒性致癌物对人类癌症负担的贡献是否相似,以及哪种类型的短期试验对于预测人类危害更具相关性,我们对在《国际癌症研究机构专论补编》第6卷和第7卷中评估了其对人类和动物致癌作用以及短期遗传毒性试验活性的物质进行了分析。确定了四组物质中遗传毒性的发生率,这四组物质包括已确定的人类致癌物(第1组,n = 30)、可能的人类致癌物(第2A组,n = 37)、可能的人类致癌物(第2B组,n = 113)以及在动物中致癌证据有限的物质(第3组的一个子集,n = 66)。第1组、2A组和2B组中的每一组都含有高比例(80 - 90%)的遗传毒性致癌物,这些致癌物也是多物种或多组织致癌物。啮齿动物中致癌效力的分布并未揭示第1组人类致癌物有任何将其与第2A组、2B组以及第3组中的许多物质区分开来的特定特征。尽管受到通过《专论》系列可获得的数据库的限制,但该分析表明,遗传毒性致癌物对人类癌症负担的增加比非遗传毒性致癌物更多。因此,继续使用以DNA染色体或突变损伤为终点的体外/体内短期试验来识别遗传毒性致癌物或在复杂混合物中分离致癌成分是完全合理的。得出的结论是:(a) 具有未知致癌潜力但在体外或体内遗传毒性试验中显示出充分活性证据的物质或复杂混合物很可能对人类构成危害;(b) 鉴于目前缺乏针对非遗传毒性致癌物的经过验证的短期试验,在这一系列遗传毒性试验中显示无活性的物质或复杂混合物应进行啮齿动物生物测定以评估其致癌性。